Article ; Online: Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study.
Diabetes, obesity & metabolism
2024 Volume 26, Issue 5, Page(s) 1605–1614
Abstract: Aim: Clinical trials showed the efficacy of sodium-glucose cotransporter 2 inhibitors for type 1 diabetes (T1D) by significant reductions in body weight and glycaemic variability, but elevated susceptibility to ketoacidosis via elevated glucagon ... ...
Abstract | Aim: Clinical trials showed the efficacy of sodium-glucose cotransporter 2 inhibitors for type 1 diabetes (T1D) by significant reductions in body weight and glycaemic variability, but elevated susceptibility to ketoacidosis via elevated glucagon secretion was a potential concern. The Suglat-AID evaluated glucagon responses and its associations with glycaemic control and ketogenesis before and after T1D treatment with the sodium-glucose cotransporter 2 inhibitor, ipragliflozin. Methods: Adults with T1D (n = 25) took 50-mg open-labelled ipragliflozin daily as adjunctive to insulin. Laboratory/clinical data including continuous glucose monitoring were collected until 12 weeks after the ipragliflozin initiation. The participants underwent a mixed-meal tolerance test (MMTT) twice [before (first MMTT) and 12 weeks after ipragliflozin treatment (second MMTT)] to evaluate responses of glucose, C-peptide, glucagon and β-hydroxybutyrate. Results: The area under the curve from fasting (0 min) to 120 min (AUC Conclusions: Ipragliflozin treatment for T1D increased postprandial glucagon secretion, which did not exacerbate postprandial hyperglycaemia but might protect against hypoglycaemia, leading to reduced glycaemic variability. The increased glucagon secretion might accelerate ketogenesis when adequate insulin is not supplied. |
---|---|
MeSH term(s) | Adult ; Humans ; 3-Hydroxybutyric Acid ; Blood Glucose ; Blood Glucose Self-Monitoring ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/drug therapy ; Glucagon/metabolism ; Glucose ; Glucosides ; Glycemic Control ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/pharmacology ; Insulin/therapeutic use ; Prospective Studies ; Thiophenes |
Chemical Substances | 3-Hydroxybutyric Acid (TZP1275679) ; Blood Glucose ; Glucagon (9007-92-5) ; Glucose (IY9XDZ35W2) ; Glucosides ; Hypoglycemic Agents ; Insulin ; ipragliflozin (3N2N8OOR7X) ; Thiophenes |
Language | English |
Publishing date | 2024-01-22 |
Publishing country | England |
Document type | Multicenter Study ; Journal Article |
ZDB-ID | 1454944-x |
ISSN | 1463-1326 ; 1462-8902 |
ISSN (online) | 1463-1326 |
ISSN | 1462-8902 |
DOI | 10.1111/dom.15458 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5442: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.